EGFR mutation + KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation + KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR mutation + KRAS mutation
|
NSCLC
|
EGFR mutation + KRAS mutation
|
NSCLC
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
EGFR mutation + KRAS mutation
|
LUAD
|
EGFR mutation + KRAS mutation
|
LUAD
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR mutation + KRAS mutation
|
CRC
|
EGFR mutation + KRAS mutation
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|